FDA Clears Novartis’ TOBI Podhaler With Post-Market Trials To Address Efficacy Concerns
This article was originally published in The Pink Sheet Daily
Company also has to validate its instructions for use of the inhaled product for CF patients with Pseudomonas aeruginosa and determine if tobramycin resistance increases.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
US FDA's advisors produce tie vote on bupivacaine extended-release solution for post-surgical analgesia; proponents valued its potential to to cut opioid use, while opponents questioned its efficacy.
However, the month may be losing its influence over the US FDA's annual submission total.